2025-11-20 00:18:58
Latest Post
SpiceJet Completes Major Restructuring, Removes US $50 Million in Liabilities
NTPC Green Energy Ltd inks MoU with The Singareni Collieries Company Ltd for development of RE Projects
UFO Moviez Enters into a Strategic Alliance with Miraj Cinemas for Exclusive Advertising Rights Across 239 Screens in 49 Cities and 72 Locations
Canara Bank marks 120th Founders Day with the opening of its 10,000th Branch in Budigere Cross, Bengaluru
DevX launches Capital One, touted as the single largest, managed office space campus across Tier II cities
Research
Angel Broking recommends Neutral on Sun Pharma - 3QFY2014 Result Update
Posted On : 2014-02-23 19:47:29( TIMEZONE : IST )
For 3QFY2014, Sun Pharmaceuticals Industries (Sun Pharma) posted results much ahead of our expectations. Sales came in at Rs. 4,287cr (vs an expected Rs. 3,700cr), posting a yoy growth of 50.3%. The growth was primarily led by exports, which rose by 61% yoy, while domestic formulations grew by 20.0% yoy. On the profitability front, the gross margin expanded by 136bp yoy to 81.7%, which aided the OPM to come in at 46.1% vs 44.2% in 3QFY2013, and higher than an expected 42.1%. Also, a higher other income during the period aided the net profit to come in at Rs. 1,531cr (vs an expected Rs. 1,054cr), a yoy growth of 73.7%. For FY2014 the company's Management has raised its growth guidance from 25% to 29% (in constant currency). We are Neutral on the stock.
Better than expected results: Sun Pharma, for 3QFY2014, posted results much ahead of our expectations. Sales came in at Rs. 4,287cr (vs an expected Rs. 3,700cr), posting a yoy growth of 50.3%. The growth was primarily led by exports, which rose by 61% yoy, while domestic formulations grew by 20.0% yoy. The key region that drove exports growth was the US, which posted a growth of 79.2% yoy and a growth of 57% yoy in US$ terms. On the profitability front, the gross margin expanded by 136bp to end the period at 81.7%, which aided the OPM to come in at 46.1% vs 44.2% in 3QFY2013, and higher than our estimate of 42.1%. Also, a higher other income during the period aided the net profit to come in at Rs. 1,531cr (vs an expected Rs. 1,054cr), a yoy growth of 73.7%.
Outlook and valuation: Sun Pharma is one of the largest and fastest growing Indian pharmaceutical companies. We expect its net sales to post a 21.0% CAGR to Rs. 16,450cr and EPS to post a 22.8% CAGR to Rs. 25.2 over FY2013-15. On account of rich valuations, we recommend a Neutral stance on the stock.
